GSK brings scientific and technical expertise to the Challenge.

Winners of the Discovery Fast Track Challenge will be given access to our world-class knowledge in drug discovery and our highly diverse compound collections. Using our expertise in drug discovery, we will design the best screening plans and we may provideĀ¹ the chemical structures of high-quality chemical tools from successful screens according to the four possible research outcomes.

Reagents and Assays

Reagents and assays are customised to identify quality chemical tools. A wide range of biochemical, biophysical, cellular and phenotypic assays can be exploited and scaled to meet lead discovery needs.

High Throughput Screening (HTS)

HTS enables the testing of millions of pure compounds using a diverse set of technologies in biochemical and cellular assays of different complexity. Our HTS chemical library consists of approximately 2 million compounds selected to enhance the success in finding high-quality molecules for lead optimisation programmes. The infrastructure in minaturisation, robotics and data analysis together with years of experience make HTS a fast and high-quality process.

DNA-Encoded Compound Library Technology (ELT)

ELT is an affinity-based selection methodology for hit identification. This technology is based on the synthesis and screening of a highly diverse collection of small molecules tagged with specific DNA sequences used as unique barcodes. Our current collection spans 94 different libraries that contain billions of unique compounds, each with its own unique DNA barcode. Our libraries exploit split and pool combinatorial chemistry to produce this diversity, while the DNA tags obviate the traditional challenge of library deconvolution.

Hit Qualification Support

After completing screening, selecting the optimal tool compound(s) from the hundreds or thousands of raw screening hits typically requires using a range of assays (e.g., biochemical, biophysical, cell-based), along with computational chemistry approaches to identify emergent structure-activity relationships. To accomplish this, GSK operates a fully integrated environment and takes a holistic computational and experimental approach. We provide both the relevant measurements and the interpretational guidance, ensuring the selected compounds possess the best chemical properties and interact with the target via a desired modality.

¹ Subject to GSK's existing internal and external obligations means that GSK has no other GSK R&D programmes working on the compound and that the compound is not bound by an external collaboration agreement between GSK and a third party, whereby GSK is not permitted to transfer or relinquish these compounds.